Immuneering Corporation

NASDAQ: IMRX · Real-Time Price · USD
3.79
0.75 (24.67%)
At close: Aug 15, 2025, 3:59 PM
3.65
-3.57%
After-hours: Aug 15, 2025, 07:49 PM EDT

Immuneering Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a 316.95K 2.08M
Cost of Revenue
n/a 764.14K 158.12K 1.15M
Gross Profit
n/a -764.14K 158.83K 926.89K
Operating Income
-64.07M -58.41M -51.74M -33.89M
Interest Income
n/a 3.61M 1.01M 169.9K
Pretax Income
-61.04M -53.47M -50.51M -33.84M
Net Income
-61.04M -53.47M -49.28M -33.54M
Selling & General & Admin
16.08M 16.25M 15.61M 8.27M
Research & Development
47.96M 41.4M 36.27M 26.54M
Other Expenses
29.27K n/a 30.05K -127.06K
Operating Expenses
64.07M 57.65M 51.9M 34.81M
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
n/a -511.87K n/a n/a
Cost & Expenses
64.07M 58.41M 52.06M 35.97M
Income Tax Expense
n/a n/a -1.23M -307.49K
Shares Outstanding (Basic)
29.98M 28.42M 26.39M 26.32M
Shares Outstanding (Diluted)
29.98M 28.42M 26.39M 26.32M
EPS (Basic)
-2.04 -1.88 -1.87 -1.27
EPS (Diluted)
-2.04 -1.88 -1.87 -1.27
EBITDA
-63.69M -58.06M -51.47M -33.68M
EBIT
-64.07M -58.41M -51.75M -33.89M
Depreciation & Amortization
385.07K 352.08K 796.79K 159.07K